This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504491-15-00

Acronym

GO40311

Enrollment

187

Registered

2023-10-10

Start date

2020-10-30

Completion date

Unknown

Last updated

2025-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human epidermal growth factor receptor (HER2)-Expressing Cancers

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Denmark, France, Italy, Netherlands, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026